Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Comparative magnitude and persistence of SARS-CoV-2 vaccination responses on a population level in Germany

Alex Dulovic, Barbora Kessel, Manuela Harries, Matthias Becker, Julia Ortmann, Johanna Griesbaum, Jennifer Jüngling, Daniel Junker, Pilar Hernandez, Daniela Gornyk, Stephan Glöckner, Vanessa Melhorn, Stefanie Castell, Jana-Kristin Heise, Yvonne Kemmling, Torsten Tonn, Kerstin Frank, Thomas Illig, Norman Klopp, Neha Warikoo, Angelika Rath, Christina Suckel, Anne Ulrike Marzian, Nicole Grupe, Philipp D. Kaiser, Bjoern Traenkle, Ulrich Rothbauer, Tobias Kerrinnes, Gérard Krause, Berit Lange, View ORCID ProfileNicole Schneiderhan-Marra, Monika Strengert
doi: https://doi.org/10.1101/2021.12.01.21266960
Alex Dulovic
1NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbora Kessel
2Helmholtz Centre for Infection Research, Braunschweig, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manuela Harries
2Helmholtz Centre for Infection Research, Braunschweig, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthias Becker
1NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia Ortmann
2Helmholtz Centre for Infection Research, Braunschweig, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johanna Griesbaum
1NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer Jüngling
1NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Junker
1NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pilar Hernandez
2Helmholtz Centre for Infection Research, Braunschweig, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela Gornyk
2Helmholtz Centre for Infection Research, Braunschweig, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephan Glöckner
2Helmholtz Centre for Infection Research, Braunschweig, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vanessa Melhorn
2Helmholtz Centre for Infection Research, Braunschweig, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefanie Castell
2Helmholtz Centre for Infection Research, Braunschweig, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jana-Kristin Heise
2Helmholtz Centre for Infection Research, Braunschweig, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yvonne Kemmling
2Helmholtz Centre for Infection Research, Braunschweig, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Torsten Tonn
3Institute of Transfusion Medicine and Immunohematology, German Red Cross, Plauen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kerstin Frank
3Institute of Transfusion Medicine and Immunohematology, German Red Cross, Plauen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Illig
4Hannover Unified Biobank, Hannover Medical School, Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Norman Klopp
4Hannover Unified Biobank, Hannover Medical School, Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neha Warikoo
2Helmholtz Centre for Infection Research, Braunschweig, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angelika Rath
2Helmholtz Centre for Infection Research, Braunschweig, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christina Suckel
2Helmholtz Centre for Infection Research, Braunschweig, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Ulrike Marzian
2Helmholtz Centre for Infection Research, Braunschweig, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicole Grupe
2Helmholtz Centre for Infection Research, Braunschweig, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philipp D. Kaiser
1NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bjoern Traenkle
1NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ulrich Rothbauer
1NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
5Pharmaceutical Biotechnology, University of Tübingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tobias Kerrinnes
6Helmholtz Institute for RNA-based Infection Research, Würzburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gérard Krause
2Helmholtz Centre for Infection Research, Braunschweig, Germany
7TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture of the Hannover Medical School and the Helmholtz Centre for Infection Research, Hannover, Germany
8German Centre for Infection Research (DZIF), partner site Hannover-Braunschweig, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Berit Lange
2Helmholtz Centre for Infection Research, Braunschweig, Germany
8German Centre for Infection Research (DZIF), partner site Hannover-Braunschweig, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: monika.strengert@helmholtz-hzi.de berit.lange@helmholtz-hzi.de nicole.schneiderhan@nmi.de
Nicole Schneiderhan-Marra
1NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nicole Schneiderhan-Marra
  • For correspondence: monika.strengert@helmholtz-hzi.de berit.lange@helmholtz-hzi.de nicole.schneiderhan@nmi.de
Monika Strengert
2Helmholtz Centre for Infection Research, Braunschweig, Germany
7TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture of the Hannover Medical School and the Helmholtz Centre for Infection Research, Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: monika.strengert@helmholtz-hzi.de berit.lange@helmholtz-hzi.de nicole.schneiderhan@nmi.de
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background While SARS-CoV-2 vaccinations were successful in decreasing COVID-19 caseloads, recent increases in SARS-CoV-2 infections have led to questions about duration and quality of the subsequent immune response. While numerous studies have been published on immune responses triggered by vaccination, these often focused on the initial peak response generated in specific population subgroups (e.g. healthcare workers or immunocompromised individuals) and have often only examined the effects of one or two different immunisation schemes.

Methods and Findings We analysed serum samples from participants of a large German seroprevalence study (MuSPAD) who had received all available vaccines and dose schedules (mRNA-1273, BNT162b2, AZD1222, Ad26.CoV2S.2 or a combination of AZD1222 plus either mRNA-1273 or BNT162b2). Antibody titers against various SARS-CoV-2 antigens and ACE2 binding inhibition against SARS-CoV-2 wild-type and the Alpha, Beta, Gamma and Delta variants of concern were analysed using a previously published multiplex immunoassay MULTICOV-AB and an ACE2-RBD competition assay. Among the different vaccines and their dosing regimens, homologous mRNA-based or heterologous prime-boost vaccination produced significantly higher antibody responses than vector-based homologous vaccination. Ad26.CoV2S.2 performance was significantly reduced, even compared to AZD1222, with 91.67% of samples being considered non-responsive forACE2 binding inhibition. mRNA-based vaccination induced a higher ratio of RBD- and S1-targeting antibodies than vector-based vaccination, which resulted in an increased proportion of S2-targeting antibodies. Previously infected individuals had a robust immune response once vaccinated, regardless of which vaccine they received. When examining antibody kinetics post-vaccination after homologous immunisation regimens, both titers and ACE2 binding inhibition peaked approximately 28 days post-vaccination and then decreased as time increased.

Conclusions As one of the first and largest population-based studies to examine vaccine responses for all currently available immunisation schemes in Germany, we found that homologous mRNA or heterologous vaccination elicited the highest immune responses. The high percentage of non-responders for Ad26.CoV2.S requires further investigation and suggests that a booster dose with an mRNA-based vaccine may be necessary. The high responses seen in recovered and vaccinated individuals could aid future dose allocation, should shortages arise for certain manufacturers. Given the role of RBD- and S1-specific antibodies in neutralising SARS-CoV-2, their relative over-representation after mRNA vaccination may explain why mRNA vaccines have an increased efficacy compared to vector-based formulations. Further investigation on these differences will be of particular interest for vaccine development and efficacy, especially for the next-generation of vector-based vaccines.

Competing Interest Statement

NSM was a speaker at Luminex user meetings in the past. The Natural and Medical Sciences Institute at the University of Tuebingen is involved in applied research projects as a fee for services with the Luminex Corporation. The other authors declare no competing interest.

Funding Statement

This work was financially supported by the Initiative and Networking Fund of the Helmholtz Association of German Research Centres (grant number SO-96), the EU Horizon 2020 research and innovation program (grant agreement number 101003480 - CORESMA), intramural funds of the Helmholtz Centre for Infection Research and the State Ministry of Baden-Wuerttemberg for Economic Affairs, Labour and Tourism (grant numbers FKZ 3-4332.62-NMI-67 and FKZ 3-4332.62-NMI-68). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the Ethics Committee of the Hannover Medical School (9086_BO_S_2020).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data is available upon request from the corresponding authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 05, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Comparative magnitude and persistence of SARS-CoV-2 vaccination responses on a population level in Germany
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Comparative magnitude and persistence of SARS-CoV-2 vaccination responses on a population level in Germany
Alex Dulovic, Barbora Kessel, Manuela Harries, Matthias Becker, Julia Ortmann, Johanna Griesbaum, Jennifer Jüngling, Daniel Junker, Pilar Hernandez, Daniela Gornyk, Stephan Glöckner, Vanessa Melhorn, Stefanie Castell, Jana-Kristin Heise, Yvonne Kemmling, Torsten Tonn, Kerstin Frank, Thomas Illig, Norman Klopp, Neha Warikoo, Angelika Rath, Christina Suckel, Anne Ulrike Marzian, Nicole Grupe, Philipp D. Kaiser, Bjoern Traenkle, Ulrich Rothbauer, Tobias Kerrinnes, Gérard Krause, Berit Lange, Nicole Schneiderhan-Marra, Monika Strengert
medRxiv 2021.12.01.21266960; doi: https://doi.org/10.1101/2021.12.01.21266960
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Comparative magnitude and persistence of SARS-CoV-2 vaccination responses on a population level in Germany
Alex Dulovic, Barbora Kessel, Manuela Harries, Matthias Becker, Julia Ortmann, Johanna Griesbaum, Jennifer Jüngling, Daniel Junker, Pilar Hernandez, Daniela Gornyk, Stephan Glöckner, Vanessa Melhorn, Stefanie Castell, Jana-Kristin Heise, Yvonne Kemmling, Torsten Tonn, Kerstin Frank, Thomas Illig, Norman Klopp, Neha Warikoo, Angelika Rath, Christina Suckel, Anne Ulrike Marzian, Nicole Grupe, Philipp D. Kaiser, Bjoern Traenkle, Ulrich Rothbauer, Tobias Kerrinnes, Gérard Krause, Berit Lange, Nicole Schneiderhan-Marra, Monika Strengert
medRxiv 2021.12.01.21266960; doi: https://doi.org/10.1101/2021.12.01.21266960

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (241)
  • Allergy and Immunology (521)
  • Anesthesia (125)
  • Cardiovascular Medicine (1425)
  • Dentistry and Oral Medicine (217)
  • Dermatology (158)
  • Emergency Medicine (292)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (585)
  • Epidemiology (10307)
  • Forensic Medicine (6)
  • Gastroenterology (528)
  • Genetic and Genomic Medicine (2637)
  • Geriatric Medicine (254)
  • Health Economics (497)
  • Health Informatics (1740)
  • Health Policy (790)
  • Health Systems and Quality Improvement (676)
  • Hematology (268)
  • HIV/AIDS (568)
  • Infectious Diseases (except HIV/AIDS) (12103)
  • Intensive Care and Critical Care Medicine (649)
  • Medical Education (273)
  • Medical Ethics (83)
  • Nephrology (291)
  • Neurology (2466)
  • Nursing (145)
  • Nutrition (379)
  • Obstetrics and Gynecology (493)
  • Occupational and Environmental Health (568)
  • Oncology (1327)
  • Ophthalmology (403)
  • Orthopedics (147)
  • Otolaryngology (238)
  • Pain Medicine (168)
  • Palliative Medicine (51)
  • Pathology (343)
  • Pediatrics (784)
  • Pharmacology and Therapeutics (330)
  • Primary Care Research (296)
  • Psychiatry and Clinical Psychology (2405)
  • Public and Global Health (5018)
  • Radiology and Imaging (895)
  • Rehabilitation Medicine and Physical Therapy (530)
  • Respiratory Medicine (682)
  • Rheumatology (309)
  • Sexual and Reproductive Health (256)
  • Sports Medicine (246)
  • Surgery (298)
  • Toxicology (45)
  • Transplantation (141)
  • Urology (108)